Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
An Open Label Study of Chronic Use of BLI400 Laxative in Constipated Adults
NCT02819310 · View on ClinicalTrials.gov ↗
Study Summary
The objective of this study is to evaluate the safety of chronic use of BLI400 laxative in constipated adults.
Conditions Studied
Interventions
- DRUG BLI400 Laxative
Study Locations (20)
Florida
- Braintree Research Site 13 — Brandon
- Braintree Research Site 3 — Brandon
- Braintree Research Site 18 — Hialeah
- Braintree Research Site 19 — Hialeah
- Braintree Research Site 4 — Miami
- Braintree Research Site 5 — Miami
- Braintree Research Site 16 — Miami
- Braintree Research Site 8 — Miami Lakes
- Braintree Research Site 17 — Palmetto Bay
- Braintree Research Site 12 — St. Petersburg
- Braintree Research Site 2 — West Palm Beach
Tennessee
- Braintree Research Site 11 — Chattanooga
- Braintree Research Site 22 — Memphis
- Braintree Research Site 10 — Nashville
California
- Braintree Research Site 14 — Corona
Kentucky
- Braintree Research Site 24 — Owensboro
Louisiana
- Braintree Research Site 15 — Lake Charles
Nevada
- Braintree Research Site 25 — Las Vegas
North Carolina
- Braintree Research Site 21 — Fayetteville
Ohio
- Braintree Research Site 6 — Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 330 participants |
| Start Date | 2016-06 |
| Est. Completion | 2017-08 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02819310
The ClinicalTrials.gov registry entry for NCT02819310 describes a study currently listed as completed. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 330 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Braintree Laboratories, which has 10 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 3 conditions, with Constipation appearing as the primary indexed condition, and to 1 intervention — of which BLI400 Laxative is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT02819310 reports 20 study locations spanning 8 distinct geographic areas — top geographies include Florida, Tennessee, California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT02819310 about?
NCT02819310 is a clinical study titled "An Open Label Study of Chronic Use of BLI400 Laxative in Constipated Adults". The objective of this study is to evaluate the safety of chronic use of BLI400 laxative in constipated adults.
What is the current status of trial NCT02819310?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 330 participants. The study started on 2016-06. Estimated completion is 2017-08.
What conditions does trial NCT02819310 study?
This clinical trial studies the following conditions: Constipation, Chronic Idiopathic Constipation, CIC. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT02819310?
The interventions under investigation include: BLI400 Laxative (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT02819310?
This trial is sponsored by Braintree Laboratories, which has 10 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT02819310 being conducted?
This trial has 20 study locations across California, Florida, Kentucky, Louisiana, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.